Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
SourceCancer Chemotherapy and Pharmacology, 85, 5, (2020), pp. 931-940
Article / Letter to editor
Display more detailsDisplay less details
Cancer Chemotherapy and Pharmacology
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.